Amarin Reports Second Quarter 2019 Financial Results and Operational Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
Amarin Corp. (AMRN) Tops Q2 EPS by 4c, Revenues Beat
July 31, 2019 5:44 AM EDTAmarin Corp. (NASDAQ: AMRN) reported Q2 EPS of $0.02, $0.04 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $100.8 million versus the consensus estimate of $99.54 million.
Record Total Revenue of $100.8 Million Achieved in Q2 2019Commercial Expansion Plans on Track in Anticipation of September 28, 2019 PDUFA Date for Vascepa®If Approved, Vascepa to Become First Prescription Therapy to Treat Patients with Underlying Cardiovascular Risk Beyond Cholesterol Management as Demonstrated in the REDUCE-IT Cardiovascular Outcomes StudyMillions of Patients in the U.S. Have Underlying Cardiovascular Risk Beyond Cholesterol... More